Prognostic value of CD44 expression in renal cell carcinoma: A systematic review and meta-analysis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Li, Xintao ^a   Ma, Xin ^a   Chen, Luyao ^a   Gu, Liangyou ^a   Zhang, Yu ^a   Zhang, Fan ^a   Ouyang, Yun ^a   Gao, Yu ^a   Huang, Qingbo ^a   Zhang, Xu ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN;

DISEASE FREE SURVIVAL; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; META ANALYSIS; METABOLISM; PATHOLOGY; PROGNOSIS; PUBLISHING;

ANTIGENS, CD44; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS; PUBLICATION BIAS;

EID: 84939632640     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13157     Document Type: Review

References (42)

1. Jemal, A. et al. Global cancer statistics. CA: a cancer journal for clinicians 61, 69-90 (2011).
2. Gupta, K., Miller, J. D., Li, J. Z., Russell, M. W., Charbonneau, C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer treatment reviews 34, 193-205 (2008).
3. Mills, E. J., Rachlis, B., O'Regan, C., Thabane, L., Perri, D. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC cancer 9, 34 (2009).
4. Nguyen, L. V., Vanner, R., Dirks, P., Eaves, C. J. Cancer stem cells: an evolving concept. Nature reviews. Cancer 12, 133-143 (2012).
5. Reya, T., Morrison, S. J., Clarke, M. F., Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
6. Bomken, S., Fiser, K., Heidenreich, O., Vormoor, J. Understanding the cancer stem cell. British journal of cancer 103, 439-445 (2010).
7. Mikami, S. et al. Expression of TNF-alpha and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas. International journal of cancer. Journal international du cancer 136, 1504-1514 (2014).
8. Wang, K. et al. Increased expression of ALDH1A1 protein is associated with poor prognosis in clear cell renal cell carcinoma. Medical oncology (Northwood, London, England) 30, 574 (2013).
9. Kim, K., Ihm, H., Ro, J. Y., Cho, Y. M. High-level expression of stem cell marker CD133 in clear cell renal cell carcinoma with favorable prognosis. Oncology letters 2, 1095-1100 (2011).
10. Moon, J. H. et al. Isolation and characterization of multipotent human keloid-derived mesenchymal-like stem cells. Stem cells and development 17, 713-724 (2008).
11. Cho, J. S. et al. Isolation and characterization of multipotent mesenchymal stem cells in nasal polyps. Experimental biology and medicine 240, 185-193 (2015).
12. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 100, 3983-3988 (2003).
13. Zoller, M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nature reviews. Cancer 11, 254-267 (2011).
14. Rodrigo, J. P. et al. Clinicopathologic significance of expression of CD44s and CD44v6 isoforms in squamous cell carcinoma of the supraglottic larynx. American journal of clinical pathology 118, 67-72 (2002).
15. Aruffo, A., Stamenkovic, I., Melnick, M., Underhill, C. B., Seed, B. CD44 is the principal cell surface receptor for hyaluronate. Cell 61, 1303-1313 (1990).
16. Orian-Rousseau, V. CD44, a therapeutic target for metastasising tumours. European journal of cancer (Oxford, England: 1990) 46, 1271-1277 (2010).
17. Bamias, A. et al. Prognostic significance of CA 125, CD44, and epithelial membrane antigen in renal cell carcinoma. Urology 62, 368-373 (2003).
18. Tawfik, O. W. et al. Prognostic significance of CD44, platelet-derived growth factor receptor alpha, and cyclooxygenase 2 expression in renal cell carcinoma. Archives of pathology & laboratory medicine 131, 261-267 (2007).
19. Paradis, V. et al. CD44 is an independent prognostic factor in conventional renal cell carcinomas. The Journal of urology 161, 1984-1987 (1999).
20. Daniel, L. et al. CD44s and CD44v6 expression in localized T1-T2 conventional renal cell carcinomas. The Journal of pathology 193, 345-349 (2001).
21. De Alava, E., Panizo, A., Sola, I., Rodriguez-Rubio, F. I., Pardo-Mindan, F. J. CD44v6 expression is related to progression in renal epithelial tumours. Histopathology 33, 39-45 (1998).
22. Gilcrease, M. Z. et al. Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence. Cancer 86, 2320-2326 (1999).
23. Matusan, K., Dordevic, G., Mozetic, V., Lucin, K. Expression of osteopontin and CD44 molecule in papillary renal cell tumors. Pathology oncology research: POR 11, 108-113 (2005).
24. Lucin, K., Matusan, K., Dordevic, G., Stipic, D. Prognostic significance of CD44 molecule in renal cell carcinoma. Croatian medical journal 45, 703-708 (2004).
25. Wu, S. T. et al. Correlation of CD44v5 expression with invasiveness and prognosis in renal cell carcinoma. Journal of the Formosan Medical Association = Taiwan yi zhi 102, 229-233 (2003).
26. Li, N. et al. Analysis of CD44 isoform v10 expression and its prognostic value in renal cell carcinoma. BJU international 85, 514-518 (2000).
27. Bonnet, D., Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature medicine 3, 730-737 (1997).
28. Basakran, N. S. CD44 as a potential diagnostic tumor marker. Saudi medical journal 36, 273-279 (2015).
29. Korski, K., Malicka-Durczak, A., Breborowicz, J. Expression of stem cell marker CD44 in prostate cancer biopsies predicts cancer grade in radical prostatectomy specimens. Polish journal of pathology: official journal of the Polish Society of Pathologists 65, 291-295 (2014).
30. Emich, H., Chapireau, D., Hutchison, I., Mackenzie, I. The potential of CD44 as a diagnostic and prognostic tool in oral cancer. Journal of oral pathology & medicine: official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology doi: 10.1111/jop.12308 (2015).
31. Jing, F. et al. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases. International journal of oncology 46, 1582-1588 (2015).
32. Nosrati, A., Naghshvar, F., Khanari, S. Cancer Stem Cell Markers CD44, CD133 in Primary Gastric Adenocarcinoma. International journal of molecular and cellular medicine 3, 279-286 (2014).
33. Wang, H. et al. Expression and Significance of CD44, CD47 and c-met in Ovarian Clear Cell Carcinoma. International journal of molecular sciences 16, 3391-3404 (2015).
34. Wang, W., Dong, L. P., Zhang, N., Zhao, C. H. Role of cancer stem cell marker CD44 in gastric cancer: a meta-analysis. International journal of clinical and experimental medicine 7, 5059-5066 (2014).
35. Bourguignon, L. Y. Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Seminars in cancer biology 18, 251-259 (2008).
36. Takahashi, S. et al. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients. Oncology reports 24, 1201-1212 (2010).
37. Chen, S. et al. CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis. PloS one 8, e56380 (2013).
38. Horst, D., Kriegl, L., Engel, J., Kirchner, T., Jung, A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer investigation 27, 844-850 (2009).
39. Brown, R. L. et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. The Journal of clinical investigation 121, 1064-1074 (2011).
40. Kan, M. et al. High-level expression of the CD44 variant sharing exon v10 in renal cancer. Japanese journal of cancer research: Gann 86, 847-853 (1995).
41. Hara, I. et al. Expression of CD44 adhesion molecules in nonpapillary renal cell carcinoma and normal kidneys. Urology 54, 562-566 (1999).
42. Chi, A. et al. Molecular characterization of kidney cancer: association of hyaluronic acid family with histological subtypes and metastasis. Cancer 118, 2394-2402 (2012).